UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Downstream of the HOX genes: Explaining conflicting tumour suppressor and oncogenic functions in cancer

International journal of cancer, 2022-06, Vol.150 (12), p.1919-1932

2022

Volltextzugriff (PDF)

Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy

The New England journal of medicine, 2016-12, Vol.375 (23), p.2246-2254

2016

Volltextzugriff (PDF)

PBX3 in Cancer

Cancers, 2020-02, Vol.12 (2), p.431

2020

Volltextzugriff (PDF)

Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results

European urology, 2018-01, Vol.73 (1), p.62-68

2018

Volltextzugriff (PDF)

Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13

Cancer Immunology, Immunotherapy, 2011-10, Vol.60 (10), p.1419-1430

2011

Volltextzugriff (PDF)

Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder Cancer

Clinical cancer research, 2019-10, Vol.25 (19), p.5818-5831

2019

Volltextzugriff (PDF)

Targeting HOX and PBX transcription factors in ovarian cancer

BMC cancer, 2010-03, Vol.10 (1), p.89-89, Article 89

2010

Volltextzugriff (PDF)

Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade

Science translational medicine, 2018-01, Vol.10 (422)

2018

Volltextzugriff (PDF)

Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study

Clinical cancer research, 2018-04, Vol.24 (7), p.1554-1561

2018

Volltextzugriff (PDF)

Targeting HOX/PBX dimers in cancer

Oncotarget, 2017-05, Vol.8 (19), p.32322-32331

2017

Volltextzugriff (PDF)

Kinase Regulation of HOX Transcription Factors

Cancers, 2019-04, Vol.11 (4), p.508

2019

Volltextzugriff (PDF)

The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon

Human gene therapy, 2009-10, Vol.20 (10), p.1119-1132

2009

Volltextzugriff (PDF)

A Phase I Study of Intravenous Oncolytic Reovirus Type 3 Dearing in Patients with Advanced Cancer

Clinical cancer research, 2008-11, Vol.14 (21), p.7127-7137

2008

Volltextzugriff (PDF)

Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer

BMC cancer, 2011-06, Vol.11 (1), p.221-221, Article 221

2011

Volltextzugriff (PDF)

Reovirus Activates Human Dendritic Cells to Promote Innate Antitumor Immunity

The Journal of immunology (1950), 2008-05, Vol.180 (9), p.6018-6026

2008

Volltextzugriff (PDF)

Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies

Clinical cancer research, 2012-04, Vol.18 (7), p.2080-2089

2012

Volltextzugriff (PDF)

Targeting the HOX/PBX dimer in breast cancer

Breast cancer research and treatment, 2012-11, Vol.136 (2), p.389-398

2012

Volltextzugriff (PDF)

The abrogation of the HOXB7/PBX2 complex induces apoptosis in melanoma through the miR‐221&222‐c‐FOS pathway

International journal of cancer, 2013-08, Vol.133 (4), p.879-892

2013

Volltextzugriff (PDF)

The Role of Circular RNAs in Pancreatic Ductal Adenocarcinoma and Biliary-Tract Cancers

Cancers, 2020-11, Vol.12 (11), p.3250

2020

Volltextzugriff (PDF)

Immune-Mediated Antitumor Activity of Reovirus Is Required for Therapy and Is Independent of Direct Viral Oncolysis and Replication

Clinical cancer research, 2009-07, Vol.15 (13), p.4374-4381

2009

Volltextzugriff (PDF)

Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis

Clinical cancer research, 2019-02, Vol.25 (4), p.1165-1173

2019

Volltextzugriff (PDF)

Tumor Infection by Oncolytic Reovirus Primes Adaptive Antitumor Immunity

Clinical cancer research, 2008-11, Vol.14 (22), p.7358-7366

2008

Volltextzugriff (PDF)

HOX transcription factors are potential targets and markers in malignant mesothelioma

BMC cancer, 2016-02, Vol.16 (87), p.85, Article 85

2016

Volltextzugriff (PDF)

HOX genes in ovarian cancer

Journal of ovarian research, 2011-09, Vol.4 (1), p.16-16, Article 16

2011

Volltextzugriff (PDF)

Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway

BMC cancer, 2012-08, Vol.12 (1), p.368-368, Article 368

2012

Volltextzugriff (PDF)

1 – 25 von 302

Suche als RSS-Feed

Aktive Filter

KollektionSpringer Nature - Connect here FIRST to enable access

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(260)
Mit Volltextzugriff
(257)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Downstream of the HOX genes: Explaining conflicting tumour suppressor and oncogenic functions in cancer

Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy

PBX3 in Cancer

Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results

Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13

Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder Cancer

Targeting HOX and PBX transcription factors in ovarian cancer

Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade

Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study

Targeting HOX/PBX dimers in cancer

Kinase Regulation of HOX Transcription Factors

The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon

A Phase I Study of Intravenous Oncolytic Reovirus Type 3 Dearing in Patients with Advanced Cancer

Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer

Reovirus Activates Human Dendritic Cells to Promote Innate Antitumor Immunity

Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies

Targeting the HOX/PBX dimer in breast cancer

The abrogation of the HOXB7/PBX2 complex induces apoptosis in melanoma through the miR‐221&222‐c‐FOS pathway

The Role of Circular RNAs in Pancreatic Ductal Adenocarcinoma and Biliary-Tract Cancers

Immune-Mediated Antitumor Activity of Reovirus Is Required for Therapy and Is Independent of Direct Viral Oncolysis and Replication

Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis

Tumor Infection by Oncolytic Reovirus Primes Adaptive Antitumor Immunity

HOX transcription factors are potential targets and markers in malignant mesothelioma

HOX genes in ovarian cancer

Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway

Aktive Filter

Suchergebnisse filtern